Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-11-21FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
FDA supplemental approval for tolmetin sodium under Atland Pharmaceuticals, LLC; the submission indicates a supplemental application proceed…
-
FDA approval · 2024-11-21FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
FDA approved a supplemental application for Tolmetin Sodium (generic tolmetin) from Atland Pharmaceuticals, LLC.
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for MELOXICAM from Zydus Pharmaceuticals USA Inc., as part of an ANDA, indicating approval of an…
-
FDA approval · 2024-11-21FDA Approved: INDOMETHACIN — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for indomethacin submitted by Chartwell RX, LLC. This action represents an approved supplement t…
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for MELOXICAM (meloxicam) under ANDA077944.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-11-21FDA Approved: CELEBREX — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Celebrex (celecoxib) filed by Viatris Specialty LLC. The approval covers changes requested i…
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (AiPing Pharmaceutical, Inc)
FDA approved a supplemental application for meloxicam from AiPing Pharmaceutical, Inc. The approval pertained to updating the labeling under…
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for meloxicam, confirming regulatory clearance for the product.
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for MELOXICAM from Cipla USA Inc., authorizing changes to an existing meloxicam product under an…
-
FDA approval · 2024-11-21FDA Approved: IBUPROFEN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for ibuprofen from Actavis Pharma, Inc.
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: Effects of Telemonitoring-supported Game-based Home Exercises in Juvenile Idiopathic Arthritis [NA]
Completed clinical trial evaluating telemonitoring-supported game-based home exercises for juvenile idiopathic arthritis to assess feasibili…
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: Exercise Programs on Gait in Children JIA [NA]
Clinical trial update indicating completion of a study evaluating exercise programs to improve gait in children with Juvenile Idiopathic Art…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Pediatric Arthritis Study of Certolizumab Pegol [Phase 3]
Results from a Phase 3 pediatric trial of certolizumab pegol for polyarticular-course juvenile idiopathic arthritis have been posted.
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) [Phase 2]
An open-label, ascending, repeated-dose Phase 2 trial evaluating sarilumab in children and adolescents with polyarticular-course juvenile id…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS [Phase 3]
This entry updates a Phase 3 clinical trial evaluating STEP-UP and STEP-DOWN therapeutic strategies for juvenile arthritis, currently recrui…
-
FDA label_change · 2024-10-10FDA Approved: SOVUNA — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for SOVUNA (hydroxychloroquine sulfate) by ANI Pharmaceuticals, Inc., indicating a label change.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission [Phase 4]
A Phase 4 clinical trial from Istituto Giannina Gaslini aims to personalize when to withdraw therapy for children with juvenile idiopathic a…
-
FDA approval · 2024-09-27FDA Approved: CELECOXIB — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Celecoxib from Actavis Pharma, Inc.
-
FDA approval · 2024-08-26FDA Approved: ADALIMUMAB-RYVK — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for ADALIMUMAB-RYVK, a biosimilar to adalimumab, submitted by Quallent Pharmaceuticals Health LL…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
ClinicalTrials.gov indicates the UCAN CAN-DU study is recruiting for a Canada-Netherlands personalized medicine network focused on childhood…
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis [NA]
A completed study evaluating the safety and efficacy of Gardasil in females with juvenile idiopathic arthritis and seronegative arthritis, w…
-
CLINICAL_TRIALS research · 2024-06-21Clinical Trial Update: SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
A clinical trial is currently recruiting to study the SARS-CoV-2 vaccination in adolescents with Juvenile Idiopathic Arthritis, led by Nante…
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis [Phase 3]
Phase 3 clinical trial assessing the efficacy of intravenous pulse therapy to induce remission in refractory juvenile idiopathic arthritis; …
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
The study is in RECRUITING and aims to stratify patients with Juvenile Idiopathic Arthritis using clinical, laboratory, and ultrasound data.…
-
FDA approval · 2024-06-03FDA Approved: METHOTREXATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for methotrexate, authorizing the generic version of the drug.